Anika Therapeutics, Inc. - Common Stock, Par Value $0.01 Per Share (ANIK)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, Par Value $0.01 Per Share
Symbol
ANIK on Nasdaq
Shares outstanding
14,033,333
Price per share
$9.61
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
12,231,313
Total reported value
$114,982,192
% of total 13F portfolios
0%
Share change
-467,783
Value change
-$5,971,104
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
113
Price from insider filings
$11.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Anika Therapeutics, Inc. - Common Stock, Par Value $0.01 Per Share (ANIK) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Caligan Partners LP 10% $14,365,651 1,435,130 Caligan Partners LP 19 Nov 2025
BlackRock, Inc. 6.8% -35% $14,147,616 -$8,737,671 963,078 -38% BlackRock, Inc. 31 Mar 2025
BlackRock Portfolio Management LLC 5.5% $7,454,957 793,359 BlackRock Portfolio Management LLC 30 Sep 2025
DIMENSIONAL FUND ADVISORS LP 4.5% $9,656,545 657,355 Dimensional Fund Advisors LP 31 Dec 2024
Trigran Investments, Inc. 1.2% -91% $1,618,745 -$13,965,184 168,400 -90% Trigran Investments, Inc. 31 Dec 2025
As of 30 Sep 2025, Anika Therapeutics, Inc. - Common Stock, Par Value $0.01 Per Share (ANIK) has 113 institutional shareholders filing 13F forms. They hold 12,231,313 shares of 14,033,333 outstanding shares (87%) .

Top 25 institutional shareholders own 77% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 1,741,762 +14% 0% $16,372,563
Trigran Investments, Inc. 12% 1,621,215 -20% 2.8% $15,239,422
Caligan Partners LP 10% 1,435,130 0% 1.9% $13,490,222
VANGUARD GROUP INC 5.6% 780,663 +0.15% 0% $7,338,232
ACADIAN ASSET MANAGEMENT LLC 4.5% 632,791 +9.9% 0.01% $5,941,000
DIMENSIONAL FUND ADVISORS LP 4.3% 601,163 -3.5% 0% $5,650,730
CAPITAL MANAGEMENT CORP /VA 3.9% 551,248 +35% 0.81% $5,181,727
BOOTHBAY FUND MANAGEMENT, LLC 3.8% 539,642 +1.9% 0.13% $5,072,635
RENAISSANCE TECHNOLOGIES LLC 3.8% 533,017 +1.1% 0.01% $5,010,360
MORGAN STANLEY 2.8% 394,741 +264% 0% $3,710,565
GEODE CAPITAL MANAGEMENT, LLC 2.4% 335,681 +4.5% 0% $3,156,398
STATE STREET CORP 2.3% 323,378 -0.3% 0% $3,039,753
D. E. Shaw & Co., Inc. 1.2% 175,315 +41% 0% $1,647,961
ENVESTNET ASSET MANAGEMENT INC 0.93% 130,809 +7.8% 0% $1,229,605
NORTHERN TRUST CORP 0.85% 119,112 +3.9% 0% $1,119,653
JACOBS LEVY EQUITY MANAGEMENT, INC 0.78% 109,814 -8% 0% $1,032,252
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.74% 103,870 -22% 0% $976,378
Cove Street Capital, LLC 0.73% 101,956 +38% 1.3% $958,386
GLOBEFLEX CAPITAL L P 0.62% 87,600 0% 0.13% $823,440
MILLENNIUM MANAGEMENT LLC 0.62% 86,874 -35% 0% $816,616
DEUTSCHE BANK AG\ 0.58% 81,290 0% 0% $764,126
TWO SIGMA INVESTMENTS, LP 0.57% 79,921 0% $751,257
MARSHALL WACE, LLP 0.53% 73,724 +224% 0% $693,006
GOLDMAN SACHS GROUP INC 0.46% 64,975 +150% 0% $610,765
Quantinno Capital Management LP 0.42% 58,594 +337% 0% $550,784

Institutional Holders of Anika Therapeutics, Inc. - Common Stock, Par Value $0.01 Per Share (ANIK) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 16,415 $157,749 -$307,845 $9.61 4
2025 Q3 12,231,313 $114,982,192 -$5,971,104 $9.40 113
2025 Q2 12,685,136 $134,203,655 -$1,529,085 $10.58 101
2025 Q1 12,677,819 $190,700,837 +$2,180,082 $15.03 107
2024 Q4 12,529,691 $206,235,517 -$14,093,626 $16.46 108
2024 Q3 13,093,708 $323,524,735 -$7,569,530 $24.70 121
2024 Q2 13,238,350 $335,327,792 -$3,265,667 $25.33 113
2024 Q1 13,404,303 $340,492,164 +$4,319,363 $25.40 119
2023 Q4 13,250,118 $300,245,422 +$6,673,700 $22.66 116
2023 Q3 13,003,869 $242,256,970 -$5,557,577 $18.63 116
2023 Q2 13,100,461 $340,372,426 +$436,229 $25.98 116
2023 Q1 13,079,037 $375,621,420 -$1,049,447 $28.72 118
2022 Q4 13,106,170 $387,952,547 -$23,669,010 $29.60 123
2022 Q3 13,466,221 $320,512,893 -$1,527,070 $23.80 114
2022 Q2 13,537,892 $302,166,866 -$732,634 $22.32 118
2022 Q1 13,595,480 $341,424,225 +$996,762 $25.11 114
2021 Q4 13,487,182 $483,258,995 +$10,255,331 $35.83 125
2021 Q3 13,151,662 $559,519,170 -$490,889 $42.56 127
2021 Q2 13,141,807 $568,895,445 -$4,270,965 $43.29 133
2021 Q1 13,310,684 $543,030,178 -$15,429,177 $40.79 144
2020 Q4 13,538,757 $612,639,033 +$244,003 $45.26 156
2020 Q3 13,592,200 $481,004,726 -$8,432,726 $35.39 153
2020 Q2 13,813,202 $520,292,852 +$34,612,076 $37.73 155
2020 Q1 13,000,312 $375,884,789 -$23,630,047 $28.91 160
2019 Q4 13,454,848 $697,513,936 -$12,549,474 $51.85 188
2019 Q3 13,671,640 $750,377,749 -$18,168,917 $54.89 191
2019 Q2 14,024,589 $569,641,989 +$37,425,161 $40.62 164
2019 Q1 13,319,121 $402,798,234 +$13,754,863 $30.24 152
2018 Q4 12,765,105 $429,002,609 -$13,458,065 $33.61 156
2018 Q3 13,139,092 $554,138,864 -$31,421,390 $42.18 153
2018 Q2 13,943,042 $446,152,896 +$47,549,513 $32.00 163
2018 Q1 12,380,690 $615,555,237 +$15,254,180 $49.72 163
2017 Q4 12,417,396 $669,502,564 -$1,448,565 $53.91 165
2017 Q3 12,404,517 $719,433,944 +$3,285,099 $58.00 163
2017 Q2 12,374,607 $610,498,457 +$26,979,854 $49.34 154
2017 Q1 11,852,436 $514,912,867 +$107,801,621 $43.44 152
2016 Q4 10,997,247 $538,411,707 -$2,604,321 $48.96 152
2016 Q3 11,084,615 $530,426,792 -$20,700,941 $47.85 159
2016 Q2 11,499,663 $616,813,180 -$31,454,369 $53.65 159
2016 Q1 12,121,173 $542,270,562 -$11,877,450 $44.72 160
2015 Q4 12,415,909 $473,859,149 -$1,414,918 $38.16 149
2015 Q3 12,475,677 $397,091,901 +$11,089,244 $31.83 135
2015 Q2 12,143,231 $401,082,257 -$15,149,040 $33.03 136
2015 Q1 12,274,379 $505,215,345 +$17,599,542 $41.17 159
2014 Q4 11,859,338 $483,081,891 +$36,845,748 $40.74 159
2014 Q3 11,043,556 $404,914,011 +$34,112,722 $36.66 150
2014 Q2 9,987,532 $462,796,042 -$6,557,083 $46.33 160
2014 Q1 10,153,818 $417,235,325 +$54,137,543 $41.10 152